- Stocks
- Pharma & Healthcare
- Rekvina Labs
Rekvina Labs share price
NSE: VINRKLBPharma & HealthcareDrug Manufacturers - Specialty & Generic
Rekvina Labs at a glance
With a market capitalisation of ₹22 Cr, it ranks 3552nd by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹1 Cr and net profit −₹0 Cr, on a standalone basis. Promoters held 41.30% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹22 CrRank 3552 on NSE
- Price to book
- -8.17×FY25
- EPS (TTM)
- −₹0.43to Q4 FY26
- ROE
- 0.0%FY25
- ROCE
- 41.3%FY25
- Debt to equity
- -0.74FY25
- Net profit margin
- 0.0%FY25
- Book value / share
- −₹0.55FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Rekvina Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | ₹0 Cr | ₹0 Cr | ₹1 Cr |
| Revenue YoY | — | — | — | — | — | — | — | — |
| Net profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit YoY | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | −15.0% | −34.3% | −8.3% |
| EPS | ₹0.00 | −₹0.11 | −₹0.04 | −₹0.07 | −₹0.06 | −₹0.06 | −₹0.21 | −₹0.10 |
Rekvina Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Operating profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr |
| Net profit | ₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | −₹0 Cr | −₹0 Cr |
| EPS (₹) | ₹0.00 | −₹0.11 | −₹0.13 | ₹0.00 | ₹0.00 | −₹0.23 |
| Cash from operations | −₹0 Cr | −₹0 Cr | −₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | −₹0 Cr |
Rekvina Labs shareholding pattern
| Holder | 30 Sep 2024 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% | 41.30% |
| Non-institutions | 58.70% | 58.70% | 58.70% | 58.70% | 58.70% | 58.70% |
Rekvina Labs vs peers
The listed Pharma & Healthcare companies nearest to Rekvina Labs by market capitalisation.
Ask anything about Rekvina Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against VINRKLB's own history. Try: “Why has VINRKLB moved over the last three months?” · “Backtest a 50-day moving-average crossover on VINRKLB over five years” · “Compare VINRKLB with SUPHA on margins and valuation”
Frequently asked questions about Rekvina Labs
What is the market cap of Rekvina Labs?
Rekvina Labs' market capitalisation is ₹22 Cr (₹22 Cr) at the 22 Oct 2026 close, ranking 3552nd among the NSE companies Pivot tracks.
What is the ROE and ROCE of Rekvina Labs?
Return on equity was 0.0% in FY25 and return on capital employed was 41.3% in FY25 (standalone figures).
Is Rekvina Labs a debt-free company?
Rekvina Labs is close to debt-free: its debt-to-equity ratio was -0.74 in FY25.
What were Rekvina Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Rekvina Labs reported revenue of ₹1 Cr and net profit of −₹0 Cr.
What is the shareholding pattern of Rekvina Labs?
As of 30 Jun 2026: promoters 41.30%, non-institutions 58.70%.
Who are Rekvina Labs' competitors?
The listed Pharma & Healthcare companies closest to Rekvina Labs by market cap are SUPHA PHARMACHE, Transgene Biote, Hamps Bio, Adeshwar Medite, Maitri and Desh Rakshak.
Is Rekvina Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Rekvina Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VINRKLB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with R · all NSE stocks · this page as text